EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing

Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.

WSJ • Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

Zacks Investment Research • Oct 14, 2026

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.6%, we present two other groups of five DGI stocks, each with moderate to high yields of up to 8%.

Seeking Alpha • Oct 10, 2026

Press Release : Availability of the aide-mémoire for Q3 2026 results

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

GlobeNewsWire • Oct 6, 2026

As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey held the initial case management conference for In re: Dupixent (dupilumab) Products Liability.

Business Wire • Oct 5, 2026

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.

24/7 Wall Street • Oct 5, 2026

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options Towns shares why protecting his health remains a priority and encourages informed conversations about COVID-19 vaccination The campaign highlights NUVAXOVID, the only FDA-approved protein-based, non-mRNA COVID-19 vaccine MORRISTOWN, N.J., Oct. 2, 2026 /PRNewswire/ -- Sanofi has partnered with 2026 NBA Champion Karl-Anthony Towns to help raise awareness about the importance of COVID-19 vaccination among those eligible during the respiratory season.

PRNewsWire • Oct 2, 2026

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Zacks Investment Research • Oct 2, 2026

Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

WSJ • Oct 1, 2026

Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

French drugmaker ​Sanofi said on Thursday it ‌would pay US partner Regeneron $1 billion upfront and up to $7 billion more ​in milestone payments to add ​four next-generation, long-acting immunology antibodies to ⁠the partnership behind their blockbuster ​eczema drug Dupixent.

Reuters • Oct 1, 2026